glp 1 shot zepbound Vial: What You Need to Know About This GLP-1 Weight Loss Medication Eli Lilly's GLP-1 outdoes Novo

FDA's April 2026 proposal to remove semaglutide and tirzepatide from the 503B bulks list - with a public comment period through June 2026 - creates a genuine decision window: buyers who enroll now are committing to a subscription before the outcome of that proposal is known

Why This Feels More Accessible Than It Is There has been no broad policy announcement opening access to GLP-1 medications across TRICARE

Views expressed in Employer Coverage are purely my own

Research published in BioScientifica confirms that GLP-1 receptors are located directly in the Ventral Tegmental Area (VTA) and the Nucleus Accumbens the parts of the brain that control wanting and craving. By dampening the dopamine hit we get from a binge, these medications can effectively decondition the brains reliance on food for pleasure

K.TullockC